Oncotelic Therapeutics, Inc.

OTCPK:OTLC Stock Report

Market Cap: US$13.4m

Oncotelic Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:OTLC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Nov 24BuyUS$8,627Vuong TrieuIndividual298,499US$0.029
23 Aug 24BuyUS$10,000Vuong TrieuIndividual500,000US$0.02

Insider Trading Volume

Insider Buying: OTLC insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of OTLC?
Owner TypeNumber of SharesOwnership Percentage
Private Companies20,111,0314.94%
General Public187,350,30646%
Individual Insiders199,828,28149.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.

Top Shareholders

Top 9 shareholders own 54% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.5%
Vuong Trieu
99,715,245US$3.3m0.3%no data
10.2%
Balaji Baktha
41,630,811US$1.4m0%no data
5.76%
Larn Hwang
23,455,990US$769.4k0%no data
4.19%
Chao Hsiao
17,073,604US$560.0k0%no data
4.12%
Autotelic Inc.
16,780,384US$550.4k0%no data
4.04%
Saranjit Saund
16,456,480US$539.8k0%no data
0.82%
Artius Bioconsulting, Llc
3,330,647US$109.2k0%no data
0.28%
Anthony Maida
1,137,314US$37.3k0%no data
0.088%
Amit Shah
358,837US$11.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 20:37
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncotelic Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Theodore O'NeillLitchfield Hills Research, LLC